Scholarlink

<p>Although hyperuricemia is associated with chronic kidney disease (CKD), the impact of uric acid (UA)-lowering drugs on CKD has been controversial. Previous investigations have primarily included xanthine oxidase inhibitors; therefore, research of dotinurad, a recently developed selective urate reabsorption inhibitor, is necessary. This retrospective study included 58 patients with CKD; of these, 29 newly initiated dotinurad and 29 initiated febuxostat. The effects of dotinurad and febuxostat on the serum UA, urinary UA-to-creatinine ratio (UUCR), and estimated glomerular filtration rate (eGFR) during 3&#xa0;months were analyzed to compare their impacts on renal function. Dotinurad and febuxostat decreased serum UA (8.40 ± 1.11 to 6.50 ± 0.80&#xa0;mg/dL [<i>p</i> &lt; 0.001] and 8.91 ± 1.21 to 6.05 ± 1.28&#xa0;mg/dL [<i>p</i> = &lt; 0.001], respectively). The UUCR increased after dotinurad (0.35 ± 0.15 to 0.40 ± 0.21&#xa0;g/gCr [<i>p</i> = 0.024]); however, it decreased after febuxostat (0.33 ± 0.12 to 0.21 ± 0.06&#xa0;g/gCr [<i>p</i> = 0.002]). The eGFR improved after dotinurad (33.9 ± 15.2 to 36.2 ± 15.9&#xa0;mL/min/1.73&#xa0;m<sup>2</sup> [<i>p</i> &lt; 0.001]). No change was observed after febuxostat treatment (33.4 ± 19.6 to 34.1 ± 21.6&#xa0;mL/min/1.73&#xa0;m<sup>2</sup>). Renal function improved only with dotinurad, thus highlighting its renoprotective effects beyond the reduction of serum UA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative assessment of the effects of dotinurad and febuxostat on the renal function in chronic kidney disease patients with hyperuricemia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月15日

查看全文
  • Tomoaki Takata,
  • Sosuke Taniguchi,
  • Yukari Mae,
  • Kana Kageyama,
  • Yudai Fujino,
  • Takuji Iyama,
  • Katsuya Hikita,
  • Takaaki Sugihara,
  • Hajime Isomoto

摘要

Although hyperuricemia is associated with chronic kidney disease (CKD), the impact of uric acid (UA)-lowering drugs on CKD has been controversial. Previous investigations have primarily included xanthine oxidase inhibitors; therefore, research of dotinurad, a recently developed selective urate reabsorption inhibitor, is necessary. This retrospective study included 58 patients with CKD; of these, 29 newly initiated dotinurad and 29 initiated febuxostat. The effects of dotinurad and febuxostat on the serum UA, urinary UA-to-creatinine ratio (UUCR), and estimated glomerular filtration rate (eGFR) during 3 months were analyzed to compare their impacts on renal function. Dotinurad and febuxostat decreased serum UA (8.40 ± 1.11 to 6.50 ± 0.80 mg/dL [p < 0.001] and 8.91 ± 1.21 to 6.05 ± 1.28 mg/dL [p = < 0.001], respectively). The UUCR increased after dotinurad (0.35 ± 0.15 to 0.40 ± 0.21 g/gCr [p = 0.024]); however, it decreased after febuxostat (0.33 ± 0.12 to 0.21 ± 0.06 g/gCr [p = 0.002]). The eGFR improved after dotinurad (33.9 ± 15.2 to 36.2 ± 15.9 mL/min/1.73 m2 [p < 0.001]). No change was observed after febuxostat treatment (33.4 ± 19.6 to 34.1 ± 21.6 mL/min/1.73 m2). Renal function improved only with dotinurad, thus highlighting its renoprotective effects beyond the reduction of serum UA.